drugset / Trial / NCT06484335
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Phase 1
Recruiting
48 enrolled
Henry M. Jackson Foundation for the Advancement of Military Medicine
US Military HIV Research Program · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI).
Timeline
- Start
- 2025-03-27
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A244d11 gp120 | Protein / enzyme biologic | — | — |
| Subject | ChAdOx1.HIVconsv62 | Vaccine | — | — |
| Subject | ChAdOx1.tHIVconsv1 | Vaccine | — | — |
| Subject | MVA.tHIVconsv4 | Vaccine | — | — |
| Subject | PGDM1400LS | Monoclonal antibody | — | — |
| Subject | VRC07-523LS | Monoclonal antibody | — | — |
| Background | Army Liposome Formulation | Other / unclassified | — | — |